...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: BIO CEO Slides Up
1
Feb 12, 2019 02:14PM
2
Feb 12, 2019 02:23PM
1
Feb 12, 2019 02:28PM
8
Feb 13, 2019 10:21AM
2
Feb 13, 2019 10:36AM
1
Feb 13, 2019 11:36AM
1
Feb 13, 2019 12:00PM
3
Feb 13, 2019 12:06PM

Feb 13, 2019 12:11PM
4
Feb 13, 2019 12:29PM
2
Feb 13, 2019 01:02PM

"OK.... but if that's how it is, then doesn't the time elapsed so far signal a ridiculously good outcome?"

Yes, but only if the accumulated number of patient years is currently greater than the originally projected/planned number of patient years. Patient years are more relevant than chronological time because it would accurately reflect enrollment and dropouts. BETonMACE was originally designed to give 3600 patient years (2400 patients with average 18 months dosing). How many patient years are we at now? Could be more than 3600. Could be less than 3600. Without this critical knowledge, it is impossible to interpret the what the current trial timeline means in terms of event rate and apabetalone effect.

BearDownAZ

2
Feb 13, 2019 02:10PM
2
Feb 13, 2019 04:40PM
3
Feb 13, 2019 05:10PM
4
Feb 13, 2019 06:51PM
3
Sep 18, 2019 03:54PM
5
Sep 18, 2019 04:37PM
5
Sep 18, 2019 05:21PM
3
Sep 18, 2019 06:11PM
4
Sep 18, 2019 06:31PM
2
Sep 18, 2019 07:00PM
4
Sep 18, 2019 09:04PM
7
Sep 18, 2019 09:29PM
1
Sep 18, 2019 09:38PM
5
Sep 18, 2019 10:26PM
3
Sep 18, 2019 11:02PM
10
Sep 19, 2019 05:07AM
1
Sep 19, 2019 08:52AM
1
Sep 19, 2019 09:46AM
4
Sep 19, 2019 09:48AM
3
Sep 19, 2019 09:57AM
4
Sep 19, 2019 11:01AM
6
Sep 19, 2019 08:25PM
7
Sep 19, 2019 08:33PM
Share
New Message
Please login to post a reply